Clinical Trials Tracker — ClinicalTrials.gov API
Pricing
$100.00 / 1,000 clinical trial records
Clinical Trials Tracker — ClinicalTrials.gov API
Track clinical trials from ClinicalTrials.gov — status, phase, conditions, sponsors and enrollment as clean JSON, one record per trial. Public regulatory data, not medical advice.
Pricing
$100.00 / 1,000 clinical trial records
Rating
0.0
(0)
Developer
NexGenData
Maintained by CommunityActor stats
0
Bookmarked
2
Total users
1
Monthly active users
an hour ago
Last modified
Categories
Share
Clinical Trials Tracker
Track clinical trials from ClinicalTrials.gov — status, phase, conditions and sponsors.
Public regulatory/health data — not medical advice.
📊 Sample Output

nct_id | overall_status | study_type | phases | conditions | lead_sponsor |
|---|---|---|---|---|---|
| NCT03525925 | COMPLETED | INTERVENTIONAL | ['PHASE1'] | ['Metastatic Malignant Solid Neoplasm'] | Ohio State University Comprehensive Cancer Center |
| NCT00354276 | UNKNOWN | INTERVENTIONAL | ['PHASE2'] | ['Leukemia'] | Vion Pharmaceuticals |
| NCT02482376 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | ['PHASE2'] | ['Breast Cancer'] | Duke University |
| NCT00433576 | COMPLETED | INTERVENTIONAL | ['PHASE1'] | ['Adenocarcinoma of the Colon', 'Adenocarcinoma of the Rectum', 'Stag… | National Cancer Institute (NCI) |
| NCT02800317 | COMPLETED | INTERVENTIONAL | ['NA'] | ['Breast Neoplasm', 'Neoadjuvant Therapy', 'Axillary Lymph Nodes', 'P… | Erasmus Medical Center |
| NCT04877717 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | ['PHASE1'] | ['Advanced Solid Cancer'] | Shanghai Hengrui Pharmaceutical Co., Ltd. |
Real rows from run ZLb2bIzQzdhoUMbmg on build 0.0.7 (2026-09-25), unedited apart from masked emails/phones and shortened long text; fields the source does not publish are empty.
⚙️ Sample inputs
This is the Store example input — the same input Apify's automated check runs — so it is proven to return rows on the current build. Paste it into the input form, or send it through the API, CLI or a schedule:
{"query": "cancer","statusFilter": [],"maxStudies": 100}
🔧 Input reference
| Field | Type | Default | What it does |
|---|---|---|---|
query | string | "cancer" | Free-text search across ClinicalTrials.gov — condition, drug, sponsor or NCT id. Example: 'glioblastoma'. |
condition | string | Filter by condition or disease. Example: 'breast cancer'. | |
sponsor | string | Filter by lead sponsor. Example: 'Pfizer'. | |
statusFilter | array of string | [] | Filter by overall study status. Empty = all. |
maxStudies | integer | 100 | Maximum studies to return (pay-per-result). |
🧾 JSON sample record
One real record from run ZLb2bIzQzdhoUMbmg (emails/phones masked, long text shortened):
{"nct_id": "NCT03525925","title": "Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors","official_title": "Pilot Study Testing the Effects of BTK Inhibitor Ibrutinib on Levels and Function of Myeloid Derived Suppressor Cells and Other Immune Subsets in Patients With Metastatic Solid Tumors","overall_status": "COMPLETED","study_type": "INTERVENTIONAL","phases": ["PHASE1"],"conditions": ["Metastatic Malignant Solid Neoplasm"],"lead_sponsor": "Ohio State University Comprehensive Cancer Center","sponsor_class": "OTHER","enrollment": 16,"start_date": "2018-07-18","completion_date": "2022-07-31","first_posted": "2018-05-16","last_update": "2024-03-18","brief_summary": "This phase I trial studies how well ibrutinib and nivolumab work in treating participants with solid tumors that have spread to other places in the body. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving ibrutinib and nivolumab may work better in treating participants with solid tumors.","locations": [{"facility": "Ohio State University Comprehensive Cancer Center","city": "Columbus","state": "Ohio","country": "United States"}],"n_locations": 1,"source_url": "https://clinicaltrials.gov/study/NCT03525925"}
💰 Pricing
| Event | Price (USD) | When it is charged |
|---|---|---|
Clinical trial record (apify-default-dataset-item) | $0.1 | Charged per clinical trial record returned (ClinicalTrials.gov). |
Pay-per-event: you pay only for what the run delivers. A run that delivers nothing bills no result events (only the actor-start event, when the actor defines one). Example: a run that delivers 100 results costs 100 × $0.1 = $10.00 plus the start fee.
🔗 Related Actors
More from the NexGenData Healthcare & FDA family:
- CDC WONDER & FluView — Public Health Data API
- CMS Dialysis Facility Compare — Provider Data API
- CMS Home Health Agencies — Provider Records API
- CMS Hospice Compare — Provider Records API
17 more in this family on the NexGenData Store page.
⏰ Run this as a monitoring subscription (recommended)
Regulatory data is monitoring data. Schedule a weekly sweep (0 8 * * 1) and catch new trials as they post — an always-on official-records feed.
📊 What you get
Clean JSON, one record per trial (full output has 18 fields):
nct_id— Nct idtitle— Titleofficial_title— Official titleoverall_status— Overall statusstudy_type— Study typephases— Phasesconditions— Conditionslead_sponsor— Lead sponsorsponsor_class— Sponsor classenrollment— Enrollment
Pricing: $0.10 per trial returned (Pay-Per-Event) — about 10 trials per $1. You are charged only for trial records delivered to the dataset; blocked or empty runs charge nothing.
🤖 Use with AI agents
Point Claude, the OpenAI Agents SDK, an n8n flow or any MCP-aware client at it and pull official records on demand.
Agentic payments (x402): Supports agentic payment via x402 — agents can call this actor with USDC, no API key required.
🔗 Related regulatory actors
FDA & public-health records family:
OpenFDA Drug · Drug Approvals · Drug Shortages · Purple Book · Warning Letters/483 · Pharma Pipeline · Adverse Events · Medical Devices
Product-safety recalls: NHTSA Recalls · NHTSA Defects · NHTSA Safety · CPSC Recalls
Agent front door — Healthcare & FDA MCP: Healthcare & FDA MCP
This actor is currently private — treated and ready for review.
Public official records and enforcement data, assembled for research and monitoring.